American Regent has announced the availability of Selenious Acid Injection.
Selenious Acid Injection is a trace element indicated in adult and pediatric patients as a source of selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Patients will require individualized dosing based on their clinical condition, nutritional requirements, and the contribution of oral or enteral selenium intake.
Selenious Acid Injection is supplied as a 10mL pharmacy bulk package vial in a strength of 600mcg/10mL. The product must be transferred to a separate parenteral nutrition container, prepared and used as an admixture in parenteral nutrition solutions.
“We are pleased to offer the first FDA approved Selenious Acid Injection – developed to reflect the American Society for Parenteral and Enteral Nutrition (ASPEN) recommendations for trace element supplementation,” stated Harsher Singh, Chief Commercial and Strategic Officer at American Regent, Inc.
Selenious Acid Injection contains aluminum that may be toxic. The product contains no more than 2500mcg/L of aluminum and has a calculated osmolarity of 108.8 mOsmol/L. Patients with impaired kidney function, including preterm neonates, who receive >4 to 5 mcg/kg/day of parenteral aluminum can accumulate aluminum to levels associated with CNS and bone toxicity. Tissue loading may occur at even lower rates of administration.
For more information visit americanregent.com.
This article originally appeared on MPR